[Relapse surveillance of patients with testicular germ cell tumor].

Surveillance des patients atteints de tumeur germinale du testicule.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 20 01 2019
revised: 15 06 2019
accepted: 20 06 2019
pubmed: 10 9 2019
medline: 8 10 2019
entrez: 10 9 2019
Statut: ppublish

Résumé

Germ-cell tumors are the most common solid tumors in young men. The follow-up of these patients is very important in their management. In stage I testicular cancer, surveillance is the standard for low-risk disease. In addition to the early detection of relapse, follow-up should be directed towards prevention, detection and treatment of late toxicity, and secondary malignancies. Follow up consists in physical examination, laboratory analysis and radiological imaging. Recently, guidelines recommend risk-adapted surveillance strategy, with a reduction of CT scans numbers, due to the recognition of the risk of ionizing radiation exposure. However, efforts to maintain adequate compliance with follow up are required.

Identifiants

pubmed: 31495441
pii: S0007-4551(19)30270-X
doi: 10.1016/j.bulcan.2019.06.006
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

903-914

Informations de copyright

Copyright © 2019. Published by Elsevier Masson SAS.

Auteurs

Emeline Orillard (E)

CHU de Besançon, oncologie, 25030 Besançon cedex, France. Electronic address: emelineorillard@gmail.com.

Elodie Klajer (E)

CHU de Besançon, oncologie, 25030 Besançon cedex, France.

Elsa Kalbacher (E)

CHU de Besançon, oncologie, 25030 Besançon cedex, France.

Florence Joly (F)

Inserm, U1086, UNICANCER, centre François Baclesse, Clinical Research Department and Medical Department, 14076 Caen, France.

Alina David (A)

CHU de Besançon, radiologie, 25030 Besançon cedex, France.

Laure Hervé (L)

CHU de Besançon, oncologie, 25030 Besançon cedex, France.

Julien Viot (J)

CHU de Besançon, oncologie, 25030 Besançon cedex, France.

Guillaume Mouillet (G)

CHU de Besançon, oncologie, 25030 Besançon cedex, France.

Johann Barkatz (J)

CHU de Besançon, urologie, 25030 Besançon cedex, France.

François Kleinclauss (F)

Inserm, UMR1098, 25020 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon, France; CHU de Besançon, urologie, 25030 Besançon cedex, France.

Antoine Thiery-Vuillemin (A)

CHU de Besançon, oncologie, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH